The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | Current & future outlooks on CAR-T therapy & bispecific antibodies in follicular lymphoma
Swetha Kambhampati, MD, City of Hope, Duarte, CA, discusses recent advances in immunotherapy for follicular lymphoma (FL), focusing on CAR-T therapy and bispecific antibodies. Dr Kambhampati explains that the advent of bispecific antibodies might change the treatment paradigm and sequencing patterns in FL due to the increased tolerability of bispecifics over CAR-T, and several bispecific antibodies are expected to be approved for FL in the near future. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
